"Emerging wet AMD therapies including Fovista and abicipar pegol (Allergan/Molecular Partners) will need to be priced competitively to Eylea and Lucentis in order to garner favorable tier placement.
Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD). The findings, ...
Key Points Interested in Eyepoint Pharmaceuticals, Inc.? Here are five stocks we like better. EyePoint Pharmaceuticals said ...
Since Roche launched its long-acting eye disease medicine Vabysmo in 2022, Bayer and Regeneron have seen the impact on sales of their rival treatment Eylea, with the U.S. biotech taking a bigger hit.
88% of EYLEA HD patients had a last assigned dosing interval of ≥12 weeks at week 156, while sustaining visual and anatomic improvements achieved in the first 96 weeks, in this extension study of the ...
For Regeneron, seven weeks can’t come soon enough. That’s when its longer-acting version of macular degeneration drug Eylea is up for a potential FDA approval. Until then however, Regeneron and ...
Oct 31 (Reuters) - U.S. drugmaker Regeneron Pharmaceuticals (REGN.O), opens new tab on Thursday reported weaker-than-expected quarterly sales of the higher dose version of its blockbuster eye disease ...
REYKJAVIK, Iceland, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Alvotech (ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results